1,265 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B Downtrend
Article Searches
Allergan PLC (AGN) Q3 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2018/10/30/allergan-plc-agn-q3-2018-earnings-conference-call.aspx?source=iedfolrf0000001 Oct 30, 2018 - AGN earnings call for the period ending September 30, 2018.
Allergan Plc (AGN) Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4215854-allergan-plc-agn-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Oct 30, 2018 - Allergan Plc (NYSE:AGN)Q3 2018 Earnings CallOctober 30, 2018 8:30 am ETExecutivesDaphne Karydas - Allergan PlcBrenton L. Saunders - Allergan PlcWilliam J. Meury - Allergan PlcC. David Nicholson - Alle
Allergan plc 2018 Q3 - Results - Earnings Call Slides https://seekingalpha.com/article/4215787-allergan-plc-2018-q3-results-earnings-call-slides?source=feed_sector_healthcare Oct 30, 2018 -
Allergan (AGN) Tops Q3 Earnings and Revenue Estimates http://www.zacks.com/stock/news/332574/allergan-agn-tops-q3-earnings-and-revenue-estimates?cid=CS-ZC-FT-332574 Oct 30, 2018 - Allergan (AGN) delivered earnings and revenue surprises of 5.99% and 1.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Weitz Value Fund Q3 2018 Quarterly Commentary https://seekingalpha.com/article/4215459-weitz-value-fund-q3-2018-quarterly-commentary?source=feed_all_articles Oct 29, 2018 - The Value Fund is a no-load stock fund designed for long-term investors. The fund is large-cap focused and looks to provide you good absolute returns over long periods of time without unnecessary risk
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals http://www.zacks.com/stock/news/332136/the-zacks-analyst-blog-highlights-allergan-regeneron-pharmaceuticals-amgen-alnylam-pharmaceuticals-and-amag-pharmaceuticals?cid=CS-ZC-FT-332136 Oct 29, 2018 - The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
Teva (TEVA) to Report Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/332222/teva-teva-to-report-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-332222 Oct 29, 2018 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast) https://seekingalpha.com/article/4215213-apple-looks-recharge-tech-sector-stocks-watch-podcast?source=feed_all_articles Oct 28, 2018 - Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks
Apple Looks To Recharge Tech Sector https://seekingalpha.com/article/4215142-apple-looks-recharge-tech-sector?source=feed Oct 27, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings http://www.zacks.com/stock/news/332054/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings?cid=CS-ZC-FT-332054 Oct 26, 2018 - We take a look at a few stocks that might deliver an earnings beat when they report next week.

Pages: 1234567891011...127

<<<Page 6>